Health activists pressure Gilead to drop price of anti-HIV jab
Accelerating global access to affordable injectable lenacapavir should be top priority, says HJI director Fatima Hassan
20 June 2025 - 05:00
UPDATED 30 June 2025 - 10:15
Health activists have urged pharmaceutical manufacturer Gilead Sciences to lower the price of its twice-yearly injection for HIV prevention.
The activists say the injection will not live up to its potential if it remains unaffordable for the governments and people who need it most...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.